Back to all webinars
Multidisciplinary management of Waldenström’s macroglobulinemia: Providing specialist care beyond hematology
Alessandra Tedeschi, Roger Owen, Michael Lunn, Véronique Leblond and Joe-Elie Salem review multidisciplinary management of Waldenström’s macroglobulinemia, including provision of specialist care beyond hematology.
Speakers
Cardiovascular toxicities associated with BTK inhibitors
No entries
Multidisciplinary management of WM: The hematologist’s perspective
Fast-forward to:
An overview of multidisciplinary management for hematologic cancers
61ae050c1b44ef0dbc70888c
Disease stage and clinical features influence multidisciplinary management of WM
61ae06f61b44ef0dbc7088af
WM comorbidities of relevance to WM multidisciplinary management
61ae082f1b44ef0dbc7088bf
Diagnosis and management of peripheral neuropathies in Waldenström’s macroglobulinemia and related IgM disorders
Fast-forward to:
An overview of neuropathy associated with paraproteins
61ae09283ebc500dae6c8f3d
Diagnosing paraprotein-related neuropathy
61ae09caf8742a0daf9e302f
Anti-MAG paraproteinemic demyelinating neuropathy
61ae0a26f8742a0daf9e3036
Treating anti-MAG paraproteinemic demyelinating neuropathy
61ae0b1ff8742a0daf9e3051
Vasculitic neuropathy in an IgM paraproteinemic patient
61ae0c693ebc500dae6c8f98
Neuropathy caused by direct invasion of nerves by WM lymphoma cells
61ae0d3b3ebc500dae6c8fae
Case study
No entries
Q&A
Fast-forward to:
How do you treat patients with WM who need treatment primarily for IgM-related disorders (e.g. neuropathy) rather than symptoms related to bulky disease?
61ae0f281b44ef0dbc70895d
What is the preferred treatment for patients with relapsed IgM-related amyloidosis?
61ae0f812fc9050db56f8393
Is rituximab maintenance therapy beneficial for patients with neuropathy and WM who have a good response to rituximab?
61ae10042fc9050db56f8399
When do you perform a nerve biopsy in patients with paraproteinemia and neuropathy as part of the diagnostic procedure?
61ae105ff8742a0daf9e30ca
There are some described cases of ibrutinib-associated neuropathy. What do you think could be the underlying mechanism?
61ae10af3ebc500dae6c900a
How do you evaluate treatment response in neuropathy, and is it useful to measure the titer of anti-MAG antibodies?
61ae11022fc9050db56f83a5
Are there any cardiological conditions that absolutely contraindicate treatment with BTK inhibitors?
61ae11502fc9050db56f83ab
Is it appropriate to reduce the ibrutinib dose after a patient experiences atrial fibrillation?
61ae11a53ebc500dae6c9021
When it is required, what is your preferred oral anticoagulant to give with BTK inhibitors? And is beta-blocker prophylaxis useful in preventing arrythmia in at-risk patients?
61ae11f41b44ef0dbc70898a